p21WAF1modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia
Open Access
- 27 October 2015
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 14 (22) , 3602-3612
Abstract
P21WAF1 is a well-characterized mediator of cell cycle arrest and may also modulate chemotherapy-induced cell death. The role of p21WAF1 in drug-induced cell cycle arrest and apoptosis of acute lymphoblastic leukemia (ALL) cells was investigated using p53-functional patient-derived xenografts (PDXs), in which p21WAF1 was epigenetically silenced in T-cell ALL (T-ALL), but not in B-cell precursor (BCP)-ALL PDXs. Upon exposure to diverse cytotoxic drugs, T-ALL PDX cells exhibited markedly increased caspase-3/7 activity and phosphatidylserine (PS) externalization on the plasma membrane compared with BCP-ALL cells. Despite dramatic differences in apoptotic characteristics between T-ALL and BCP-ALL PDXs, both ALL subtypes exhibited similar cell death kinetics and were equally sensitive to p53-inducing drugs in vitro, although T-ALL PDXs were significantly more sensitive to the histone deacetylase inhibitor vorinostat. Transient siRNA suppression of p21WAF1 in the BCP-ALL 697 cell line resulted in a moderate depletion of the cell fraction in G1 phase and marked increase in PS externalization following exposure to etoposide. Furthermore, stable lentiviral p21WAF1 silencing in the BCP-ALL Nalm-6 cell line accelerated PS externalization and cell death following exposure to etoposide and vorinostat, supporting previous findings. Finally, the Sp1 inhibitor, terameprocol, inhibited p21WAF1 expression in Nalm-6 cells exposed to vorinostat and also partially augmented vorinostat-induced cell death. Taken together, these findings demonstrate that p21WAF1 regulates the early stages of drug-induced apoptosis in ALL cells and significantly modulates their sensitivity to vorinostat.Keywords
This publication has 59 references indexed in Scilit:
- EVI1 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid CellsPLOS ONE, 2013
- Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot StudyJournal of Cancer, 2012
- p53-independent Epigenetic Repression of the p21WAF1 Gene in T-cell Acute Lymphoblastic LeukemiaJournal of Biological Chemistry, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trialBlood, 2009
- p21 in cancer: intricate networks and multiple activitiesNature Reviews Cancer, 2009
- Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing programPediatric Blood & Cancer, 2009
- The Multiple Battles Fought by Anti-Apoptotic p21Cell Cycle, 2007
- p21 Blocks Irradiation-Induced Apoptosis Downstream of Mitochondria by Inhibition of Cyclin-Dependent Kinase–Mediated Caspase-9 ActivationCancer Research, 2006
- Procaspase 3/p21 complex formation to resist Fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase ACell Death & Differentiation, 2000